Actively Recruiting
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Led by Grit Biotechnology · Updated on 2025-09-15
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
G
Grit Biotechnology
Lead Sponsor
T
Tongji Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
CONDITIONS
Official Title
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily enrolled in the study and signed an informed consent form
- Willing and able to follow the study protocol
- Expected to survive more than 12 weeks
- Completed any previous systemic treatment at least 4 weeks or 5 half lives before planned treatment
You will not qualify if you...
- History of organ transplantation, splenectomy, or stem cell transplantation
- History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before enrollment requiring systemic anticoagulant therapy
- Received systemic corticosteroids at a dose of at least 10 mg/day prednisone equivalent within 7 days before GT719 infusion, except inhaled corticosteroids
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
Research Team
D
Daishi Tian
CONTACT
W
Wei Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here